Interview

Absci is a generative artificial intelligence (AI) drug creation company with goals of bringing better biologics to patients more quickly. Here, DDW Editor Reece Armstrong speaks to Sean McClain, the Founder and CEO of Absci about how generative AI is being used within drug discovery and the company’s work in the antibodies sector. RA: Could […]

The latest sponsored DDW Sitting Down With podcast is now available for your listening pleasure. The podcast features Steve Wedge, Chief Scientific Officer of Cancer Research Horizons and Mike Waring, Head of Academic Medicinal Chemistry at Cancer Research Horizons. They discuss the work Cancer Research Horizons is conducting at its site in Newcastle University; how […]

The latest sponsored DDW Sitting Down With podcast features Steve Wedge, Chief Scientific Officer of Cancer Research Horizons and Mike Waring, Head of Academic Medicinal Chemistry at Cancer Research Horizons. They discuss the work Cancer Research Horizons is conducting at its site in Newcastle University; how Cancer Research Horizons operates within its academic/industry interface; how […]

John Maher, Leucid Bio, tells Megan Thomas about his work and offers valuable advice to others in this field. MT: Where do you work, and can you tell us what you’re working on at the moment? JM: I am Chief Scientific Officer of a CAR T-cell spin-out company called Leucid Bio. I am also a Clinician Scientist […]

The latest sponsored DDW Sitting Down With podcast is now live. Professor Ruth Roberts, Co-Founder ApconiX, and Claire Sadler, Project Toxicologist, discuss the benefits of carrying out a target safety assessment (TSA) during drug discovery and development whenever a biological target is going to be modulated. The speakers outline how TSAs can be used throughout the […]

In the latest sponsored DDW Sitting Down With podcast Professor Ruth Roberts, Co-Founder ApconiX, and Claire Sadler, Project Toxicologist, discuss the benefits of carrying out a target safety assessment (TSA) during drug discovery and development whenever a biological target is going to be modulated. The speakers outline how TSAs can be used throughout the drug discovery […]

At IBM Research, a group of scientists and researchers from around the globe is working to support the power of the scientific method to invent what’s next for IBM, its clients, and the world. Joshua Smith, PhD, IBM TJ Watson Research Center, speaks with DDW’s Megan Thomas about AI, and the acceleration and discovery of […]

Dr Stephen Barat, Senior Vice President and Therapeutics Division Head at HTG Molecular Diagnostics tells DDW how transcriptomics is driving drug discovery and precision medicines. DDW: Could you explain the process of transcriptomics?  SB: Transcriptomics is the study of genomic RNA transcripts in a biological system. RNA transcript expression levels can provide insight into underlying […]

The Psychiatry Consortium and the British Neuroscience Association recently published their ‘Guiding Principles for Robust Target Validation in Psychiatry’. Dr Ekta Patel, Psychiatry Consortium Partnership Manager, spoke to DDW’s Diana Spencer about how the guide can help researchers to create a target validation package and the need for new therapeutic targets in this underfunded specialty.  […]

Mike McCully, CEO of Gate Neurosciences, speaks to DDW’s Diana Spencer about the company’s pipeline of next-generation antidepressants and why this could be the most exciting time in the history of psychiatry. DS: How has our understanding of the brain developed in the last 70 years?  MM: Although our understanding of the brain is still […]